Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.50 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.46 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.46 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14925933 | 0.86 | GPR119 (0.42) | GPR119CKS1BSKP1SKP2MAPT | |
| SCHEMBL25707196 | 0.85 | GPR119 (0.54) | GPR119SMARCA2SMARCA4PBRM1LMNA | |
| SCHEMBL14927204 | 0.85 | GPR119 (0.54) | GPR119SMARCA2SMARCA4PBRM1LMNA | |
| SCHEMBL31247616 | 0.84 | GPR119 (0.52) | GPR119SMARCA2SMARCA4PBRM1LMNA | |
| SCHEMBL30176849 | 0.84 | SMARCA2 (0.54) | GPR119SMARCA2SMARCA4PBRM1LMNA | |
| SCHEMBL14912467 | 0.84 | SMARCA2 (0.54) | GPR119SMARCA2SMARCA4PBRM1LMNA | |
| SCHEMBL14912289 | 0.84 | SMARCA2 (0.54) | GPR119SMARCA2SMARCA4PBRM1LMNA | |
| SCHEMBL14924376 | 0.84 | SMARCA2 (0.54) | GPR119SMARCA2SMARCA4PBRM1LMNA | |
| SCHEMBL30512308 | 0.84 | SMARCA2 (0.54) | GPR119SMARCA2SMARCA4PBRM1LMNA | |
| SCHEMBL24649919 | 0.82 | GPR119 (0.52) | GPR119SMARCA2SMARCA4PBRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773639-B1 | ALKYLATED PIPERAZINE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| US-9115152-B2 | Alkylated piperazine compounds | GENENTECH, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150094302-A1 | ALKYLATED PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-8946213-B2 | Alkylated piperazine compounds | GENENTECH, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140221365-A1 | ALKYLATED PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221365-A1 | ALKYLATED PIPERAZINE COMPOUNDS | BTK, SYK, LCK | GPR119 2675/4885SMARCA2 2868/4885SMARCA4 2713/4885 |
| US-20150094302-A1 | ALKYLATED PIPERAZINE COMPOUNDS | BTK, SYK, LCK | GPR119 2675/4885SMARCA2 2868/4885SMARCA4 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.